Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 31, 2007

Silence Therapeutics and Quark Pharmaceuticals Amend AtuRNAi Agreement

  • Silence Therapeutics and Quark Pharmaceuticals reported an expansion of their current strategic technology licensing agreement.

    In April 2005 the companies signed an option and license agreement, which provided Quark with access to Silence Therapeutics’ siRNA technology, AtuRNAi.

    The expanded agreement provides Quark with options to nonexclusive licenses to develop additional molecules against three specific targets using AtuRNAi. The terms of the amendment will entitle Silence Therapeutics to milestone payments and a royalty on product sales after exercise of the options by Quark.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »